ClinicalTrials.gg
CompletedNCT02170220Updated Jan 5, 2016Results posted

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

A Phase 1 interventional study of Vortioxetine in Severe Hepatic Impairment, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics of vortioxetine and its metabolites Lu AA34443 and Lu AA39835 following a single oral dose administration of vortioxetine 5 mg in participants with severe hepatic impairment compared to healthy participants.

Read the detailed description

The drug being tested in this study is called vortioxetine. Vortioxetine is being tested to assess how it moves throughout the body in people with severe hepatic impairment compared to people with normal hepatic function. This study looked at lab results in people who took vortioxetine.

The study enrolled 12 participants. Participants were assigned to one of the two treatment groups based on their hepatic function (severe hepatic impairment vs. normal hepatic function). All participants in both groups will receive one vortioxetine 5-mg tablet.

This single-center trial was conducted in the United States. The overall time to participate in this study was up to 58 days. Participants made 2 visits to the clinic, including one 12-day period of confinement to the clinic, and were contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Severe Hepatic Impairment

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is aged 18 to 75 years, inclusive, at the time of informed consent and first study medication dose.
  4. Weighs at least 50 kg and has a (BMI) between 19 and 38 kg/m\^2, inclusive at Screening.
  5. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 30 days after last dose.
  6. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
  7. Has a resting pulse and heart rate (as read on [ECG]) between 51 and 100 beats per minutes (bpm), inclusive. For healthy participants in good physical condition and aged 18 to 45 years, inclusive, the lower limit is 45 bpm.
  8. Has a negative result at screening on the fecal occult blood screen.

    Healthy Participants (Normal Hepatic Function):

  9. The participant, in opinion of the investigator, is in good health as determined by a prestudy physical examination, medical history, vital signs, ECG, and the results of blood biochemistry, hematology, and serology tests, and urinalysis.

    Participants with severe hepatic impairment:

  10. Has been classified as having severe hepatic impairment as defined by the classification system.
  11. Has case record notes demonstrating stable biochemistry as judged by the investigator prior to Screening.
  12. Has case record notes demonstrating physical signs consistent with a clinical diagnosis of liver impairment (eg, liver firmness to palpation, splenic enlargement, spider angiomas, palmar erythema, parotid hypertrophy, testicular atrophy, ascites, gynecomastia).
  13. For participants with hepatic encephalopathy, the condition does not, in the investigator's opinion, interfere with the participant's ability to provide an appropriate informed consent. (Participants who have severe encephalopathy receive a score of 3 or 4. The score reflects the degree of encephalopathy off treatment. This will be documented in the source.)

Exclusion criteria

Exclusion Criteria:

General:

  1. Has received any compound within 45 days prior to first dose of study medication.
  2. Has received vortioxetine (Lu AA21004) in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. Has received or donated more than 400 mL of blood or blood products within the 45 days preceding the beginning of the study or planned to donate blood during the study.
  5. Has a history of or allergies to vortioxetine or related compounds with same mechanism of action including any associated .
  6. Has a medical history of, or presence of, gastric or duodenal ulceration, gastritis, recent head injury or any other trauma within 1 week of Screening, extensive ecchymoses, hemoptysis, gingival bleeding, hematemesis, repeated or significant nose bleeds, periorbital hematoma, retinal detachment, menorrhagia, hematuria, or melena.
  7. Has had an acute, illness within 30 days prior to the first dose of study medication.
  8. Has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic, or nonperipheral vascular surgery within 6 months prior to the study medication.
  9. Has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
  10. Has taken any medications, supplements or food products except for those allowed for hepatically impaired participants, or approved by Takeda on a case-by-case basis.
  11. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
  12. If male, the participant intends to donate sperm during the course of this study or for 30 days thereafter.
  13. Has poor peripheral venous access.
  14. Has a serum creatinine level greater than 1.5 mg/dL at Screening or Day -1 (Check-in).
  15. Has active stage 3 or 4 encephalopathy.
  16. Has a diastolic blood pressure >100 mm Hg or a systolic blood pressure >160 mm Hg (supine) at Screening or Day -1.
  17. Has an orthostatic blood pressure ≥25 mm Hg (based on the difference between supine and standing [1 minute] systolic blood pressure) at Screening or Day 1.
  18. Has a known history of infection.
  19. Has a positive test result for surface antigen.
  20. The participant's interval (QTc, Bazett correction) is >450 millisecond (msec) for men and >470 msec for women at Screening or at Check-in as read on the printout of the and evaluated by the investigator.
  21. Has a history or clinical manifestations of significant illness such as renal insufficiency, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, rheumatologic, urologic, immunologic, infectious, skin and subcutaneous tissue disorders, or psychiatric or mood disorders (including any past suicide attempt). For hepatically impaired participants, previously known conditions associated with liver disease are not excluded.
  22. Exercises extensively in his/her normal life, that is, marathon running, triathlons, physical sports at a contest level, etc.
  23. Answers positive to any suicidal ideation and/or suicidal behavior questions during administration of the Columbia-Suicide Severity Rating Scale (C-SSRS) [7-9] at Screening.
  24. Is unwilling or unable to comply with the protocol or scheduled appointments.
  25. Is unable to understand verbal and/or written English or any other language for which a certified translation of the approved is available.
  26. The participant, in the opinion of the investigator, is unlikely to comply with the clinical trial protocol or deemed unsuitable for any other reason.
  27. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic units per day) within 1 year prior to the Screening Visit (1 unit=250 mL of beer or 20 mL of spirits or 1 glass [118 mL] of wine). Participants with severe hepatic dysfunction who test positive on the urine drug screen due to prescription drug use will be allowed to participate if approved by the principal investigator and the sponsor's medical monitor.

    Healthy Participants (Normal Hepatic Function):

  28. Has any clinically significant abnormal findings on the medical history, physical exam, ECG, or clinical laboratory tests that, in the opinion of the investigator, preclude study participation.
  29. Has a hepatic and/or endocrine disorder.
  30. Has a positive test result for antibody to virus.
  31. Has an or aspartate transaminase level of greater than 1.5 × (ULN) at Screening or Day -1 (Check-in), active liver disease, active gall bladder disease, or jaundice.
  32. Has a predisposition to easy bruising or bleeding, anemia, thrombocytopenia, or a known history, or history in a first-degree relative, of bleeding disorders (including Von Willebrand's disease or hemophilia A and B).
  33. Has a positive test for fecal occult blood.

    Participants with severe hepatic impairment:

  34. Has clinically significant laboratory abnormalities except for those parameters influenced by hepatic impairment.
  35. Has any serious illness except for controlled hypertension or diabetes and those problems associated with the primary diagnosis of hepatic impairment or other diseases that are approved by the principal investigator and the sponsor's medical monitor.
  36. Has a clinical exacerbation of liver disease (i.e, abdominal pain, nausea, vomiting, anorexia, or fever) within the 2-week period before the administration of study drug.
  37. Has clinical demonstrable, massive, tense ascites.
  38. Has evidence of acute viral hepatitis within 1 month prior to the administration of study medication.
  39. Has evidence of hepatorenal syndrome.
  40. Has a known history of bleeding disorders (including Von Willebrand's disease or hemophilia A and B).
  41. Has active alcohol abuse or dependence as defined by , Fourth Edition.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Vortioxetine 5 mg: Normal Hepatic Function Cohort

    Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 5 mg: Severe Hepatic Impairment Cohort

    Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.

    Drug: Vortioxetine

Interventions

  • Vortioxetine tablets

    Also known as: Lu AA21004, BRINTELLIX

06

What researchers measure

Primary outcomes

  1. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine

    (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  2. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443

    (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  3. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835

    (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  4. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine

    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  5. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443

    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  6. Cmax: Maximum Observed Plasma Concentration for Vortioxetine

    Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  7. Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443

    Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  8. Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835

    Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  9. AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine

    AUC(0-tlqc)u is a measure of total unbound plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]u).

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  10. AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine

    AUC(0-inf)u is a measure of total unbound plasma exposure to the drug from time zero extrapolated to infinity.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

  11. Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine

    Maximum Observed Unbound Plasma Concentration (Cmaxu) is the peak unbound plasma concentration of a drug after administration, obtained directly from the unbound plasma concentration-time curve.

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose

07

Results

Posted Jan 5, 2016

Participant flow

Participants took part in the study at 1 investigative site in the United States from 09 July 2014 (first participant signed the informed consent form) to 01 December 2014.

Participant flow — Overall Study
MilestoneVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
Started66
Completed66
Not completed00

Outcome measures

PrimaryAUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine

(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine166.955 ± 45.1656188.663 ± 68.5380
PrimaryAUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443

(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA3444388.614 ± 53.147871.942 ± 48.9356
PrimaryAUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835

(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA398351.143 ± 1.26400.078 ± 0.1903
PrimaryAUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine

AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine187.202 ± 52.8692288.053 ± 148.7612
PrimaryAUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443

AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443122.899 ± 39.2417124.708 ± 46.8665
PrimaryCmax: Maximum Observed Plasma Concentration for Vortioxetine

Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Vortioxetine
ng/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
Cmax: Maximum Observed Plasma Concentration for Vortioxetine2.078 ± 0.46751.670 ± 0.6135
PrimaryCmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443

Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443
ng/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA344432.654 ± 1.60181.374 ± 0.7849
PrimaryCmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835

Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835
ng/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA398350.029 ± 0.03240.008 ± 0.0190
PrimaryAUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine

AUC(0-tlqc)u is a measure of total unbound plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]u).

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine1.611 ± 0.49371.653 ± 0.6882
PrimaryAUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine

AUC(0-inf)u is a measure of total unbound plasma exposure to the drug from time zero extrapolated to infinity.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng*hr/mL
AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
ng*hr/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine1.806 ± 0.56852.558 ± 1.5242
PrimaryCmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine

Maximum Observed Unbound Plasma Concentration (Cmaxu) is the peak unbound plasma concentration of a drug after administration, obtained directly from the unbound plasma concentration-time curve.

Time frame:
Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Reported as:
Mean · ng/mL
Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine
ng/mLVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine0.020 ± 0.00560.014 ± 0.0053

Adverse events

Collected over The first dose of study drug to within 32 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine 5 mg: Normal Hepatic Function Cohort—0/6 (0%)0/6 (0%)
Vortioxetine 5 mg: Severe Hepatic Impairment Cohort—0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventVortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment Cohort
VomitingGastrointestinal disorders0/61/6
Blood potassium increasedInvestigations0/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Mean50.3 ± 2.5854.8 ± 6.7952.6 ± 5.43
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Female112
Male5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Hispanic or Latino6612
Not Hispanic or Latino000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
White6612
Region of Enrollment
Region of Enrollment(participants)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
United States6612
Height
Height(cm)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Mean169.3 ± 10.31165.7 ± 10.41167.5 ± 10.06
Weight
Weight(kg)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Mean80.65 ± 13.26182.17 ± 29.03881.41 ± 21.537
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vortioxetine 5 mg: Normal Hepatic Function CohortVortioxetine 5 mg: Severe Hepatic Impairment CohortTotal
Mean28.02 ± 2.92729.43 ± 7.55428.73 ± 5.512

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Miami
    Miami, Florida, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2014
First posted
Jun 23, 2014
Start
Jul 2014
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Results first posted
Jan 5, 2016
Last update
Jan 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02170220
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Jul 2014
Primary completion
Nov 2014
Completion
Dec 2014
Results posted
Jan 5, 2016
Last update
Jan 5, 2016

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion